TY - JOUR
TI - Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study
AU - Duell, E.J.
AU - Lujan-Barroso, L.
AU - Sala, N.
AU - Deitz McElyea, S.
AU - Overvad, K.
AU - Tjonneland, A.
AU - Olsen, A.
AU - Weiderpass, E.
AU - Busund, L.-T.
AU - Moi, L.
AU - Muller, D.
AU - Vineis, P.
AU - Aune, D.
AU - Matullo, G.
AU - Naccarati, A.
AU - Panico, S.
AU - Tagliabue, G.
AU - Tumino, R.
AU - Palli, D.
AU - Kaaks, R.
AU - Katzke, V.A.
AU - Boeing, H.
AU - Bueno-de-Mesquita, H.B.
AU - Peeters, P.H.
AU - Trichopoulou, A.
AU - Lagiou, P.
AU - Kotanidou, A.
AU - Travis, R.C.
AU - Wareham, N.
AU - Khaw, K.-T.
AU - Ramon Quiros, J.
AU - Rodríguez-Barranco, M.
AU - Dorronsoro, M.
AU - Chirlaque, M.-D.
AU - Ardanaz, E.
AU - Severi, G.
AU - Boutron-Ruault, M.-C.
AU - Rebours, V.
AU - Brennan, P.
AU - Gunter, M.
AU - Scelo, G.
AU - Cote, G.
AU - Sherman, S.
AU - Korc, M.
JO - International Journal  of Cancer
PY - 2017
VL - 141
TODO - 5
SP - 905-915
PB - Wiley-Liss, Inc.
SN - 0020-7136
TODO - 10.1002/ijc.30790
TODO - biological marker;  microRNA;  microRNA 106b;  microRNA 10a;  microRNA 10b;  microRNA 155;  microRNA 21 3p;  microRNA 21 5p;  microRNA 212;  microRNA 30c;  unclassified drug;  microRNA;  tumor marker, adult;  age distribution;  aged;  Article;  blood sampling;  cancer diagnosis;  cancer risk;  case control study;  cohort analysis;  controlled study;  diet restriction;  female;  follow up;  human;  major clinical study;  male;  pancreas adenocarcinoma;  pancreas adenoma;  priority journal;  prospective study;  protein blood level;  quantitative analysis;  receiver operating characteristic;  reverse transcription polymerase chain reaction;  sex ratio;  time factor;  area under the curve;  blood;  genetics;  middle aged;  pancreas carcinoma;  pancreas tumor;  polymerase chain reaction;  sensitivity and specificity, Adult;  Aged;  Area Under Curve;  Biomarkers, Tumor;  Carcinoma, Pancreatic Ductal;  Case-Control Studies;  Female;  Humans;  Male;  MicroRNAs;  Middle Aged;  Pancreatic Neoplasms;  Polymerase Chain Reaction;  Prospective Studies;  ROC Curve;  Sensitivity and Specificity
TODO - Noninvasive biomarkers for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and disease risk stratification are greatly needed. We conducted a nested case-control study within the Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate prediagnostic microRNAs (miRs) as biomarkers of subsequent PDAC risk. A panel of eight miRs (miR-10a, -10b, -21-3p, -21-5p, -30c, -106b, -155 and -212) based on previous evidence from our group was evaluated in 225 microscopically confirmed PDAC cases and 225 controls matched on center, sex, fasting status and age/date/time of blood collection. MiR levels in prediagnostic plasma samples were determined by quantitative RT-PCR. Logistic regression was used to model levels and PDAC risk, adjusting for covariates and to estimate area under the receiver operating characteristic curves (AUC). Plasma miR-10b, -21-5p, -30c and -106b levels were significantly higher in cases diagnosed within 2 years of blood collection compared to matched controls (all p-values <0.04). Based on adjusted logistic regression models, levels for six miRs (miR-10a, -10b, -21-5p, -30c, -155 and -212) overall, and for four miRs (-10a, -10b, -21-5p and -30c) at shorter follow-up time between blood collection and diagnosis (≤5 yr, ≤2 yr), were statistically significantly associated with risk. A score based on the panel showed a linear dose-response trend with risk (p-value = 0.0006). For shorter follow-up (≤5 yr), AUC for the score was 0.73, and for individual miRs ranged from 0.73 (miR-212) to 0.79 (miR-21-5p). © 2017 UICC
ER -